(tobramycin ophthalmic solution) 0.3%
TOBREX® (tobramycin ophthalmic solution) 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections. Each mL of TOBREX solution contains: Active: tobramycin 0.3% (3 mg). Preservative: benzalkonium chloride 0.01% (0.1 mg). Inactives: boric acid, sodium sulfate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and purified water. TOBREX (tobramycin ophthalmic solution) 0.3% has a pH range between 7.0 and 8.0. Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.
TOBREX (tobramycin ophthalmic solution) 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX. Clinical studies have shown tobramycin to be safe and effective for use in children.
Published Studies Related to Tobrex (Tobramycin Ophthalmic)
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. [2011.01]
CONCLUSION: ST provides a fast and effective treatment of acute blepharitis compared to azithromycin. Initial therapy with the combination of tobramycin/dexamethasone provides faster inflammation relief than azithromycin for moderate to severe blepharitis/blepharoconjunctivitis.
Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. 
BACKGROUND/AIMS: To evaluate the benefit of adding a nonsteroid agent to an antibiotic/steroid combination after uneventful phacoemulsification, adopting a weekly follow-up, to gain insight into the optimal duration of postoperative treatment and to examine whether risk factors for inflammation exist... CONCLUSION: The addition of ketorolac did not seem to offer any additional benefit in terms of inflammation-related signs. Four weeks appeared as an adequate treatment interval. Special attention should be paid to patients with pseudoexfoliation. Copyright (c) 2010 S. Karger AG, Basel.
[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis] [2010.04]
INTRODUCTION: Bacterial conjunctivitis is characterized by hyperemia and discharge of one or both eyes. These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%... CONCLUSIONS: Azithromycin 1.5% for 3 days (six drops) was as effective as tobramycin for 7 days (36 drops). Furthermore, patients on azithromycin presented earlier clinical cure on Day 3 than patients on tobramycin. Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis. Copyright 2010 Elsevier Masson SAS. All rights reserved.
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. [2008.01]
PURPOSE: To compare the steroid-induced intraocular pressure (IOP) and other ocular adverse effects of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension with those of dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension... CONCLUSIONS: Loteprednol/tobramycin was significantly less likely to produce elevations in IOP than was dexamethasone/tobramycin in healthy subjects treated for 28 days. Both loteprednol etabonate/tobramycin and dexamethasone/tobramycin were well tolerated with low risks for systemic AEs and ocular AEs other than elevation in IOP for dexamethasone/tobramycin.
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. [2008.01]
CONCLUSIONS: LE/T satisfied the condition of non-inferiority to DM/T in decreasing the signs and symptoms of ocular inflammation associated with blepharokeratoconjunctivitis. Subjects treated with DM/T experienced more of an increase in IOP. Limitation: Although the single-masked design of this study could be considered a limitation, care was taken to ensure that the investigator was masked.
Clinical Trials Related to Tobrex (Tobramycin Ophthalmic)
Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study [Completed]
This study assesses the aerosol delivery characteristics (measured by in vivo lung
deposition, nebulization time, serum tobramycin concentrations, and pharmacokinetic
parameters) and safety of tobramycin inhalation solution administered for inhalation by PARI
eFlow rapid electronic nebulizer (no compressor) vs. PARI LC PLUS Jet Nebulizer (with
compressor) in healthy subjects and in subjects with cystic fibrosis.
Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis [Recruiting]
Cystic fibrosis is the most common inherited life limiting condition which affects children.
Patients with it develop lung infections which become difficult to clear, and damage the
lungs. These are treated with antibiotics (such as tobramycin) into the vein (termed
"intravenous antibiotics"). This has without doubt improved survival. However, all
treatments have side effects. Tobramycin can cause kidney damage. The investigators have
preliminary data that suggests that administering tobramycin in the morning may be safer for
the kidneys than administering it in the evening.
The investigators plan to approach children and adults with cystic fibrosis whose doctors
have decided to administer a course of intravenous tobramycin. The investigators will
randomly allocate them to receive it at either 0800h or 2200h. The investigators will
measure the rate at which the body eliminates tobramycin from the bloodstream, by measuring
the amount of tobramycin in the blood stream after administering the antibiotic. For each
patient the study will last for the duration of the course of antibiotics. This is decided
by the doctor looking after the patient (rather than the researcher), and would typically be
14 days. The investigators will also measure substances in the blood and urine
("biomarkers") which are sensitive indicators of low levels of kidney injury. The
investigators will monitor lung function and lung bacteria in both the groups to ensure that
the patients in both groups improve by the same amount.
If the preliminary data are proved correct, this research will allow investigators to
improve the safety profile of tobramycin, one of the most widely prescribed drugs in cystic
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® [Recruiting]
The purpose of this study is to demonstrate that Tobrineb®/Actitob®/Bramitob® is
non-inferior to TOBI® in primary efficacy variable, forced expiratory volume in one second
(FEVā) percent of predicted normal, and to compare their safety in patients with cystic
fibrosis and chronic infection of the lungs with P. aeruginosa.
Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study [Completed]
This study assesses the aerosol delivery characteristics (measured by nebulization time,
serum and sputum tobramycin pharmacokinetic parameters) and safety of tobramycin administered
for inhalation by PARI eFlow rapid electronic nebulizer (no compressor) vs. PARI LC PLUS Jet
Nebulizer (with compressor) in subjects with cystic fibrosis.
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years [Recruiting]
This study will investigate the efficacy of inhaled TOBI treatment for early infections of
P. aeruginosa in paediatric patients with cystic fibrosis.
Reports of Suspected Tobrex (Tobramycin Ophthalmic) Side Effects
Wrong Drug Administered (3),
Anterior Chamber Cell (2),
Conjunctival Hyperaemia (2),
Swelling Face (2),
Dermatitis Allergic (1),
Device Material Issue (1),
Post Procedural Complication (1),
Anaphylactic Shock (1),
Disease Progression (1), more >>